Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST RA trial
2024-517112-30-00Phase 4Authorised
- Sponsor
- Medisch Spectrum Twente
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of filgotinib, triamcinolone acetonide, methotrexate, adalimumab, tocilizumab and 2 more in rheumatoid arthritis (RA) (2 arms), sponsored by Medisch Spectrum Twente. Primary endpoint: Rheumatoid arthritis remission at 3 months. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-517112-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517112-30-00.